Unknown OBSERVATIONAL NCT01329471

Functional Role of RUNX1 Mutations in the Etiology of Acute Myeloid Leukemia (AML)

Sponsor: Hillel Yaffe Medical Center

Updated 6 times since 2017 Last updated: Apr 5, 2011 Started: Apr 30, 2011 Primary completion: Apr 30, 2012 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Acute Myeloid Leukemia and is currently ongoing. Hillel Yaffe Medical Center leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status
Jun 2018 — Jan 2021 [monthly]

Unknown Status
Apr 2018 — Jun 2018 [monthly]

Unknown Status

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Unknown Status NA

First recorded

Apr 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hillel Yaffe Medical Center
Weizmann Institute of Science

Data source: Hillel Yaffe Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hadera, Israel